

# BIOMARKER-DRIVEN TREATMENT DECISION IN METASTATIC NSCLC

**HALL 407**  
SINGAPORE

## Chairs

Marina Garassino, Italy  
Ross Soo, Singapore

This educational activity is provided by ESMO and supported by Lilly Oncology.



**FRIDAY, 22 NOVEMBER 2019**  
12:45 – 14:15

12:45 Introduction  
*Ross Soo, Singapore*

12:50 Immune-checkpoints inhibitors (ICI) in non-oncogenic addicted mNSCLC  
*Marina Garassino, Milan, Italy*

13:15 EGFR mutant mNSCLC: Single agent or in combination?  
*Fabrice Barlesi, Marseille, France*

13:40 Future development in the use of biomarkers  
*Ross Soo, Singapore*

14:05 Conclusion  
*Marina Garassino, Milan, Italy*

